Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

HµrelStaticDog™, Hµrel Corporation’s In Vitro Cell Culture of Canine (Dog) Liver Cells, to be Presented at Toxicology Conference

Published: Thursday, April 11, 2013
Last Updated: Thursday, April 11, 2013
Bookmark and Share
Data highlight benefits of new tool for predicting drug toxicity in humans before clinical trials begin - important milestone in drug development evolution.

Hurel Corporation announced that the results of toxicological evaluations performed on HµrelStaticDog™, Hurel’s new, patent-pending method of culturing actual liver cells from the canine (dog) species, will be highlighted as a part of UCB’s keynote overview of the current state of the art of in vitro models to use in early toxicology assessment to detect human hepatotoxic drugs.  The UCB presentation will take place at ADME and Predictive Toxicology 2013, the toxicology symposium to be held in Barcelona, Spain on April 11th at 2:15PM.

The study results derived from HµrelStaticDog™ represent a culmination of a multi-year collaboration between UCB and Hurel under which this new pre-clinical analytic tool was developed.  UCB funded the development of HurelStaticDog™ and has collaborated with Hurel in its characterization and validation testing.

Dr. Leslie Z. Benet, Professor of Bioengineering  and Therapeutic Sciences at the University of California, San Francisco and Head of Hurel’s Scientific Advisory Board, said in connection with the upcoming presentation: “The HµrelStaticDog™ pre-clinical tool represents an important milestone in the evolution of the drug development process, for two reasons.  First, as the R&D collaboration data that will be presented in Barcelona shows, HµrelStaticDog™ is a powerful new in vitro tool for predicting the potential toxicity of drugs in humans well before the clinical trial stage.  And second, because regulatory agencies, such as the FDA and EMA, require testing of every new drug candidate on at least one non-human, “large animal” species such as dog, HµrelStaticDog™ represents a critically important new in vitro, cell-based vehicle for predicting the outcome of animal tests conducted in dogs.  That ability to predict in vivo outcomes in dogs by in vitro testing on HµrelStaticDog™ may be expected to improve the efficient performance of animal testing and thereby help reduce the over-all number of animal tests performed, while also contributing to a reduction in the rate of late-stage failures in human clinical trials.”

HµrelStaticDog™ constitutes the first instance of an advanced, high-functioning, in vitro liver cell culture system comprised of actual living cells from the canine species, which is characterized for use in pre-clinical research activities. HµrelStaticDog™ is expected to find application in the evaluation of the safety (i.e., toxicological) risks of prospective drug candidates, as well as of the metabolic and other pharmacokinetic properties of those drug candidates.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Optivia and Hurel Form Technology and Marketing Alliance
Firms partner to improve understanding of in vitro/in vivo correlation for transporter-mediated hepatic clearance, drug-drug interactions, and drug-induced liver injury.
Thursday, April 30, 2015
Hurel® Corporation Completes Investment from Johnston Associates
Biotech investment veteran Robert F. Johnston joins Hurel investor group.
Wednesday, October 08, 2014
Scientific News
Ketamine Metabolism Lifts Depression
NIH-funded team finds rapid-acting, non-addicting agent in mouse study.
Faster, Cheaper Way to Produce New Antibiotics
A novel way of synthesising a promising new antibiotic has been identified by scientists at the University of Bristol.
Process Contaminants in Vegetable Oils and Foods
Glycerol-based process contaminants found in palm oil, but also in other vegetable oils, margarines and some processed foods, raise potential health concerns for average consumers of these foods in all young age groups, and for high consumers in all age groups.
Known Genetic Risk Factors for Endometrial Cancer Doubles
An international collaboration of researchers has identified five new gene regions that increase a woman’s risk of developing endometrial cancer, one of the most common cancers to affect women, taking the number of known gene regions associated with the disease to nine.
Improving Natural Killer Cancer Therapy
Vanderbilt University researchers discover transcription factor critical for NK cell expansion. Findings could lead to increased therapeutic efficacy.
Molecular Mechanism For Generating Specific Antibody Responses Discovered
Study could spur more ways to treat autoimmune disease, develop accurate vaccines.
Monovar Drills Down Into Cancer Genome
Rice, MD Anderson develop program to ID mutations in single cancer cells.
It’s Now Easier To Go With The Flow
Rice University tool simplifies comparison of flow cytometry data for laboratories.
Autism, Cancer Share a Remarkable Number of Risk Genes
Researchers with the UC Davis Comprehensive Cancer Center, MIND Institute identify more than 40 common genes.
Number Of Known Genetic Risk Factors For Endometrial Cancer Doubled
An international collaboration of researchers has identified five new gene regions that increase a woman’s risk of developing endometrial cancer, one of the most common cancers to affect women, taking the number of known gene regions associated with the disease to nine.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!